Illumina (NASDAQ:ILMN) Earns Sell (D+) Rating from Weiss Ratings

Illumina (NASDAQ:ILMNGet Free Report)‘s stock had its “sell (d+)” rating reiterated by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also recently commented on the stock. Barclays increased their target price on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a research report on Thursday, October 2nd. Evercore ISI reduced their target price on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday. Morgan Stanley increased their target price on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research report on Monday, August 4th. Stephens set a $110.00 price objective on shares of Illumina and gave the stock an “overweight” rating in a research report on Monday, August 4th. Finally, Canaccord Genuity Group raised their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $123.56.

View Our Latest Research Report on Illumina

Illumina Stock Performance

NASDAQ:ILMN opened at $97.78 on Wednesday. The company has a fifty day moving average of $98.47 and a two-hundred day moving average of $90.11. The stock has a market capitalization of $15.03 billion, a PE ratio of 12.38, a P/E/G ratio of 2.33 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMNGet Free Report) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts forecast that Illumina will post 4.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Sicart Associates LLC boosted its stake in Illumina by 45.8% during the third quarter. Sicart Associates LLC now owns 83,123 shares of the life sciences company’s stock worth $7,894,000 after buying an additional 26,118 shares during the period. Aaron Wealth Advisors LLC boosted its stake in Illumina by 342.6% during the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock worth $995,000 after buying an additional 8,109 shares during the period. GAMMA Investing LLC boosted its stake in Illumina by 21.8% during the third quarter. GAMMA Investing LLC now owns 3,003 shares of the life sciences company’s stock worth $285,000 after buying an additional 538 shares during the period. Corient Private Wealth LLC boosted its stake in Illumina by 28.7% during the second quarter. Corient Private Wealth LLC now owns 29,352 shares of the life sciences company’s stock worth $2,800,000 after buying an additional 6,541 shares during the period. Finally, Valeo Financial Advisors LLC boosted its stake in Illumina by 43.4% during the second quarter. Valeo Financial Advisors LLC now owns 3,643 shares of the life sciences company’s stock worth $348,000 after buying an additional 1,102 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

(Get Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

See Also

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.